Alabama is currently home to 1225 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Birmingham, Mobile, Huntsville and Anniston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Pilot of Reconnecting to Internal Sensations and Experiences in Undergraduates
NCT05285111
Recruiting
Project RISE is a randomized control trial. The intervention consists of four modules that focus on multiple aspects of interoception including: body awareness, body sensations/movement, eating, health and self-care, emotional awareness, and understanding the self in relation to others. The comparator condition is called "Health Habits" and is matched for time and attention; participants complete modules related to healthy habits such as financial planning, hygiene, stretching, and healthy eatin... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/29/2024
Locations: Auburn University, Auburn, Alabama
Conditions: Suicidal Ideation, Eating Disorder Symptom
Register for Updates
The Impact of Insomnia on Pain in HIV
NCT04298658
Recruiting
The overall objective of this application is to investigate the impact of insomnia on pain, physical functioning, and inflammation in people living with HIV. The two aims of this study to determine 1) whether insomnia promotes increased sensitivity and inflammatory reactivity to pain stimuli, and 2) if weekly fluctuations in insomnia burden drive changes in inflammation, pain severity, and physical functioning in people living with HIV. This research could help confirm insomnia as a therapeutic... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/26/2024
Locations: UAB, Birmingham, Alabama
Conditions: HIV, Insomnia
Register for Updates
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
NCT05507203
Recruiting
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrin... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
07/25/2024
Locations: Digestive Health Specialists of the Southeast, Dothan, Alabama
Conditions: Ulcerative Colitis
Register for Updates
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
NCT05507216
Recruiting
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrin... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
07/25/2024
Locations: University of Alabama -Birmingham, Birmingham, Alabama
Conditions: Ulcerative Colitis
Register for Updates
MYLUNG Consortium Part 3: Observational Study
NCT05885698
Recruiting
This longitudinal study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2024
Locations: Southern Cancer Center, PC, Daphne, Alabama
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC
NCT05363280
Recruiting
This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients who need ≥2nd line treatment .
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/12/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Small Cell Lung Cancer
Register for Updates
ARrest RESpiraTory Failure From PNEUMONIA
NCT04193878
Recruiting
This research study seeks to establish the effectiveness of a combination of an inhaled corticosteroid and a beta agonist compared to placebo for the prevention of acute respiratory failure (ARF) in hospitalized patients with pneumonia and hypoxemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2024
Locations: University of Alabama Birmingham - Main & Highlands, Birmingham, Alabama
Conditions: Pneumonia, Hypoxemia, Acute Respiratory Failure, COVID-19 Pneumonia
Register for Updates
Early Intervention to Promote Cardiovascular Health of Mothers and Children
NCT06272045
Recruiting
Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) is a cluster randomized clinical trial, funded by the National Heart Lung \& Blood Institute. The study is designed to test the effectiveness of home visiting intervention to promote cardiovascular health and reduce disparities in maternal and early childhood cardiovascular health. Sites, in partnership with evidence-based home visiting programs, are recruiting 6400 participants in total (i.e., 3200 parent-dyads... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/08/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cardiovascular Health
Register for Updates
Therapeutic Mechanisms of Epidural Spinal Cord Stimulation
NCT05556902
Recruiting
The purpose of this study in patients undergoing routine care epidural spinal cord stimulation (SCS) is to determine 1) whether SCS reduces arterial blood pressure (BP) in patients which chronic low back pain and hypertension, 2) whether higher baseline BP (i.e., hypertension) predicts reductions in pain following SCS, and finally 3) whether different SCS waveforms elicits stimulus-evoked compound action potentials (ECAPs) in spinal cord and at the cortex (electroencephalography, and magnetoench... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
07/08/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Blood Pressure, Low Back Pain, Hypertension
Register for Updates
Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus
NCT05314738
Recruiting
Clinical Trial to Evaluate the Safety and Efficacy of Corneal Cross-linking in Subjects with Keratoconus.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
07/04/2024
Locations: Glaukos Investigative Site, Dothan, Alabama
Conditions: Progressive Keratoconus
Register for Updates
Non-Invasive Monitoring of Traumatic Brain Injury Progression Using the Infrascanner (MOBI-1)
NCT04893837
Recruiting
MOBI-1 is a multicenter clinical trial that will evaluate the use of the Infrascanner for the monitoring of traumatic intracranial hematomas.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
07/03/2024
Locations: UAB Hospital, Birmingham, Alabama
Conditions: Brain Injuries, Traumatic
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates